Azura Ophthalmics

About

Headcount over time

Offices

Q&A

What is Azura Ophthalmics' primary focus?

Azura Ophthalmics is a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, such as Meibomian Gland Dysfunction (MGD), Dry Eye Disease (DED), and Contact Lens Discomfort (CLD).

When was Azura Ophthalmics founded?

Azura Ophthalmics was founded in 2013.

What is the status of Azura Ophthalmics' lead product candidate?

Azura Ophthalmics' lead product candidate, AZR-MD-001, an investigational ophthalmic keratolytic targeting MGD, is currently in Phase 3 clinical trials.

How much funding has Azura Ophthalmics raised in total?

Azura Ophthalmics has raised a total of $37.2 million USD across multiple funding rounds.

When did Azura Ophthalmics complete its Series C funding round and who were the lead investors?

Azura Ophthalmics completed its Series C funding round in October 2020, raising $20 million USD. Lead investors included OrbiMed and TPG Biotech.

Who are the co-founders of Azura Ophthalmics?

The co-founders of Azura Ophthalmics are Yair Alster, who serves as Co-founder and Chief Technology Officer, and Omer Rafaeli, Co-founder and Director of Scientific Research.

Who is the Chief Executive Officer of Azura Ophthalmics?

Marc Gleeson was appointed Chief Executive Officer of Azura Ophthalmics in October 2017.

What is Azura Ophthalmics' current employee count?

As of August 2026, Azura Ophthalmics has 10 employees.

Team · 15

Yair Alster

Founder · Co-founder and Chief Technology Officer

Omer Rafaeli

Founder · Co-founder and Director of Scientific Research

Marc Gleeson

Chief Executive Officer

Charles Bosworth

Chief Medical Officer

Hila Barash

Chief Research and Development Officer

Patty Delaney

Global Head of Project Management

Shimon Nahum

Senior Manager Formulation and CMC

Abby Aharonov

Office Manager

Steven Altschuler

Board Chair

Erez Chimovits

Partner

Chris Nave

Founding Partner and Managing Director, Brandon Capital

Heather Preston

Director, Oxford Biomedica

Guy Katsav

Managing Director, Healthcare Investments, Ganot Capital

Anat Naschitz

Board Member

Ashwin Agarwal

Chief Financial Officer

Sectors & technology